ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF

Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-4-1bb antibody and use thereof

Provided is an anti-4-1 BB antibody or an antigen-binding fragment thereof, and uses thereof.

Antibodies to a-synuclein and uses thereof

The present invention relates to anti-a-synuclein antibodies, which preferentially recognize a-synuclein aggregates, and uses for detection, diagnosis, and/or treatment or prevention of a variety of diseases or disease symptoms related thereto due to accumulation of a-synuclein aggregates by using the anti-a-synuclein antibodies.

Anti-4-1BB antibody and use thereof

Provided is an anti-4-1BB antibody or an antigen-binding fragment thereof, and uses thereof.

Bispecific antibody to a-syn/igf1r and use thereof

The present invention relates to a bispecific antibody binding specifically to a-synuclein and IGF1R and a use of the bispecific antibody in preventing, treating, and/or diagnosing a-synucleinopathies, which are diseases related to a-synuclein or an aggregate thereof. In the present invention, an a-syn antibody or an antigen binding fragment thereof is allowed to pass the blood-brain barrier and to exert the function thereof in the brain, and the half-life is prolonged so that the medicinal efficacy can be maintained for a long period of time.

Bispecific anti-her2/anti-4-1bb antibody and its use

anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo. são fornecidos um anticorpo biespecífico anti-4-1bb/anti-her2 e uma composição farmacêutica e um método para tratar e/ou prevenir um câncer usando o mesmo. bispecific anti-her2/anti-4-1bb antibody and use thereof. a bispecific anti-4-1bb/anti-her2 antibody and a pharmaceutical composition and a method of treating and/or preventing a cancer using the same are provided.

Bispecific antibody to a-syn/igf1r and use thereof

The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bi-specific antibody for the prevention, treatment and / or diagnosis of synucleinopatheis associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.

Anti-her2/anti-4-1bb bispecific antibody and use thereof

Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-her2/anti-4-1bb bispecific antibody and use thereof

ANTIBODIES TO alpha-SYNUCLEIN AND USES THEREOF

The present invention relates to an anti-alpha-synuclein antibody preferentially recognizing alpha-synuclein aggregates and a use of detection, diagnosis, and/or treatment or prevention of various diseases caused by accumulation of alpha-synuclein aggregates, or their related symptom diseases by using the anti-alpha-synuclein antibody.

Bispecific Antibody to A-Syn/IGF1R and Use Thereof

The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bi-specific antibody for the prevention, treatment and/or diagnosis of synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.

Anti-4-1BB antibody and use thereof

Provided is an anti-4-1BB antibody or an antigen-binding fragment thereof, and uses thereof.

Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof

The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.

ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途

【課題】アルファ－シヌクレインおよびＩＧＦ１Ｒに特異的に結合する二重特異抗体、前記二重特異抗体を含む薬学組成物、ならびに前記二重特異抗体を製造する方法を提供する。【解決手段】ａ）抗α－シヌクレイン（抗α－ｓｙｎ）抗体またはその抗原結合断片、ならびにｂ）（ｉ）特定の配列を含む重鎖相補的決定領域（ＣＤＲ）１（Ｈ－ＣＤＲ１）、特定の配列を含むＨ－ＣＤＲ２および特定の配列を含むＨ－ＣＤＲ３を含む、重鎖可変領域（ＶＨ）、および（ｉｉ）特定の配列を含む軽鎖ＣＤＲ１（Ｌ－ＣＤＲ１）、特定の配列を含むＬ－ＣＤＲ２および特定の配列を含むＬ－ＣＤＲ３を含む、軽鎖可変領域（ＶＬ）を含む、抗ＩＧＦ１Ｒ抗体またはその抗原結合断片を含む、抗α－シヌクレイン／抗ＩＧＦ１Ｒ二重特異抗体である。【選択図】なし

Bispecific antibody to a-syn/igf1r and use thereof

The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.